|
| Reasons for the use of combined PPI and alginate-antacids | ||||||
| Increase in the onset of action | Better control of the disease | Persistence of symptoms | Decrease in nocturnal acid breakthrough | I do not use this combination | To avoid increase in PPI doses | Other | |
| Symptoms |
|
|
|
|
|
|
|
| Heartburn | 501 (33.6) | 311 (20.9) | 212 (14.2) | 210 (14.1) | 92 (6.2) | 58 (3.9) | 107 (7.2) |
| Regurgitation | 208 (14.0) | 348 (23.3) | 188 (12.6) | 358 (24.0) | 137 (9.2) | 88 (5.9) | 164 (11.0) |
| Distention | 136 (9.1) | 377 (25.3) | 198 (13.3) | 47 (3.2) | 376 (25.2) | 56 (3.8) | 301 (20.2) |
| Epigastric pain | 377 (25.3) | 423 (28.4) | 202 (13.5) | 124 (8.3) | 150 (10.1) | 76 (5.1) | 139 (9.3) |
| Gastroesophageal diseases |
|
|
|
|
|
|
|
| Nonerosive GERD | 452 (30.3) | 306 (20.5) | 169 (11.3) | 166 (11.1) | 142 (9.5) | 91 (6.1) | 165 (11.1) |
| Erosive GERD (esophagitis) | 259 (17.4) | 457 (30.7) | 183 (12.3) | 221 (14.8) | 98 (6.6) | 101 (6.8) | 172 (11.5) |
| Peptic ulcer disease | 199 (13.3) | 573 (38.4) | 216 (14.5) | 126 (8.5) | 132 (8.9) | 99 (6.6) | 146 (9.8) |
| Helicobacter pylori infection | 132 (8.9) | 482 (32.3) | 153 (10.3) | 73 (4.9) | 318 (21.3) | 64 (4.3) | 269 (18.0) |
| NSAIDs gastropathy | 273 (18.3) | 421 (28.2) | 182 (12.2) | 67 (4.5) | 205 (13.7) | 67 (4.5) | 276 (18.5) |
| Non-ulcer dyspepsia | 219 (14.7) | 389 (26.1) | 218 (14.6) | 81 (5.4) | 247 (16.6) | 78 (5.2) | 259 (17.4) |